Cangrelor bulk supplier for pharma manufacturers

Cangrelor 50 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 50 mg

Reference Brands: Kengreal (USA/EU)

Cangrelor 50 mg lyophilised powder vials for intravenous use, a fast-acting reversible P2Y12 antiplatelet for the cardiac catheter laboratory. Offered to hospital pharmacies, importers, distributors and cardiology tender buyers.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Cangrelor? List it or send an offer →

Product Description:

Cangrelor is an intravenous antiplatelet medicine, an ATP analogue that blocks the platelet P2Y12 receptor directly and reversibly. Unlike clopidogrel it needs no liver activation, so inhibition begins within minutes of the bolus. It also wears off fast: the half-life is a few minutes and platelet function recovers within about an hour of stopping. This page lists the 50 mg vial of lyophilised powder. It is made for the catheter laboratory, where an antiplatelet that switches on and off quickly helps during coronary stenting.

Cangrelor is given with aspirin to adults undergoing percutaneous coronary intervention who have not had an oral P2Y12 inhibitor, or cannot take one. A weight-based bolus is followed by an infusion for at least two hours or the length of the procedure, whichever is longer. Bleeding is the main risk. Pharmacists check the switch to oral therapy: ticagrelor can be given during or straight after the infusion, but clopidogrel and prasugrel only once it stops. Vials are reconstituted with water for injections and diluted in saline or glucose 5%.

Sourcing notes. Cangrelor is a prescription-only hospital medicine registered nationally, with generics filed on CTD or ACTD dossiers. Unopened vials are kept at controlled room temperature, so ordinary pharmaceutical transport is enough, but check stability for zone IVb if shipping into hot, humid regions. Ask for a CoA per batch with sterility, endotoxins and reconstitution time, the sterile-site GMP certificate and a CoPP. Compare impurity profile with the reference product. State vials per carton and cartons needed.

Cangrelor — third party manufacturing & bulk supply

Cangrelor 50 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Cangrelor is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Cangrelor listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Cangrelor →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Cangrelor is used as an intravenous antiplatelet agent to reduce the risk of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). It is especially useful in patients who have not been pretreated with oral P2Y12 inhibitors or who are unable to take oral antiplatelet therapy.

Cangrelor is a synthetic adenosine triphosphate analog. It is chemically designed to reversibly inhibit platelet activation by targeting the P2Y12 receptor.

Cangrelor is marketed under the trade names Kengreal in the United States and Kengrexal in the European Union and the United Kingdom.

Cangrelor was developed by The Medicines Company. It is currently marketed by Chiesi Farmaceutici in the EU and UK, and by Chiesi USA for the US market.

The generic name is cangrelor.

The brand names are Kengreal and Kengrexal.

Cangrelor is manufactured in GMP-approved pharmaceutical facilities, with production and supply distributed across the USA and Europe according to regional regulatory approvals.